Q4 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Analysts at HC Wainwright issued their Q4 2027 earnings per share estimates for Genmab A/S in a research note issued to investors on Monday, October 19th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of $0.61 per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.20 per share.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. New Street Research set a $43.00 target price on shares of Genmab A/S in a report on Wednesday, July 22nd. Morgan Stanley set a $42.00 target price on shares of Genmab A/S in a report on Tuesday. Guggenheim raised their target price on Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Finally, TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and raised their target price for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $43.39.

Genmab A/S Trading Up 4.1%

NASDAQ:GMAB opened at $38.50 on Tuesday. The firm has a market capitalization of $24.03 billion, a P/E ratio of 26.62, a P/E/G ratio of 1.73 and a beta of 0.81. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The company has a fifty day moving average of $34.51 and a 200 day moving average of $29.86. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $40.17.

Institutional Trading of Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. Capital Square LLC purchased a new position in Genmab A/S during the 3rd quarter valued at $219,000. Frank Rimerman Advisors LLC bought a new position in Genmab A/S in the 3rd quarter worth $244,000. Terra Nova Asset Management LLC raised its holdings in Genmab A/S by 6.7% in the 3rd quarter. Terra Nova Asset Management LLC now owns 68,527 shares of the company’s stock worth $2,445,000 after purchasing an additional 4,288 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 20.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,792 shares of the company’s stock worth $171,000 after purchasing an additional 814 shares during the period. Finally, Juncture Wealth Strategies LLC lifted its position in shares of Genmab A/S by 42.0% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 10,424 shares of the company’s stock worth $372,000 after purchasing an additional 3,083 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.